Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions

Although the global incidence of CRC is expected to reach 3.2 million cases by 2040 [1], the age-standardized mortality rate worldwide has been declining over the last decades [2]. At diagnosis, 25  % of people will present with stage IV disease and nearly 60 % of patients with stage II-III CRC will develop post-operative recurrence [3]. The prognosis of patients with metastatic (m)CRC is heterogeneous and while the 5-year overall survival (OS) is generally around 12 %, certain subgroups may achieve 5-year OS rates of up to 40 % following resection of liver metastases [4].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research